Dana Investment Advisors, Inc. Aurinia Pharmaceuticals Inc. Transaction History

Dana Investment Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$6.66 - $12.39 $8,697 - $16,181	1,306 Added 2.66%	50,459 $379,000
Q2 2022 Aug 15, 2022	SELL	$8.95 - $12.8 $28,836 - $41,241	-3,222 Reduced 6.15%	49,153 $494,000
Q1 2022 May 12, 2022	SELL	$10.05 - $22.48 $10,271 - $22,974	-1,022 Reduced 1.91%	52,375 $648,000
Q4 2021 Feb 09, 2022	SELL	$17.78 - $33.08 $269,953 - $502,253	-15,183 Reduced 22.14%	53,397 $1.22 Million
Q3 2021 Nov 12, 2021	SELL	$10.93 - $23.55 $370,734 - $798,792	-33,919 Reduced 33.09%	68,580 $1.52 Million
Q2 2021 Aug 10, 2021	SELL	$10.0 - $14.52 $48,400 - $70,276	-4,840 Reduced 4.51%	102,499 $1.33 Million
Q1 2021 May 13, 2021	BUY	$12.3 - $18.73 $1.32 Million - $2.01 Million	107,339 New	107,339 $1.39 Million

210

58.2M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.1B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Dana Investment Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Dana Investment Advisors, Inc. with notifications on news.